UK pharmaceutical company Masters Speciality Pharma reported on Tuesday the availability of Neuropad in Brazil for the rapid and reliable screening test for diabetic foot syndrome in the country.
Neuropad, which was reportedly launched at the Brazilian Congress of Diabetes held from the 16 – 18 October 2019 in Natal, Brazil, was developed by the German company, TRIGOcare International GmbH.
Diabetic foot syndrome arises from peripheral neuropathy in the foot as a result of diabetes. Peripheral neuropathy may affect up to half of diabetic patients and can lead to foot ulceration and amputation in severe cases. In Brazil over 12.4 million adults have diabetes.
The company added tha5t Neuropad detects the level of moisture in the feet. Reduced moisture from the sweat glands is associated with sub-motor dysfunction, an early sign of peripheral diabetic neuropathy. Neuropad is a unique, patented, adhesive pad impregnated with anhydrous cobalt II chloride that is applied to the sole of each foot and indicates adequate sweat production by means of a blue (dry) to pink (moist) colour change. It is non-invasive, painless and can be administered at-home or in-clinic providing a result in 10-15 minutes.
In addition, the clinical efficacy of this simple screening Neuropad test has been determined in >40 clinical studies involving >3000 diabetic patients and multivariate statistical analysis has shown that diabetic patients with an abnormal Neuropad result were 16 times more likely to develop foot ulceration compared with those having a normal result, concluded the company.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes